Clarify CACNA1A

Welcome to the CACNA1A Foundation blog: updates on current research, advocacy efforts,
therapy options, community activities and real life experiences of caregivers.

Lisa Manaster Lisa Manaster

XEN007

For those in the US, there is some exciting news regarding a new medication being developed for our children with Gain of Function variants. The CACNA1A Foundation recently had a call with Xenon Pharmaceuticals, a clinical-stage biopharmaceutical company committed to developing innovative therapeutics that will improve the lives of patients with neurological disorders and central nervous system (CNS) conditions, with a focus on epilepsy.

Read More